Chronic Kidney Disease

The global burden of CKD attributable to high BMI has shown a consistent upward trend from 1990 to 2021, with projections further increases by 2050.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

Check out the latest renal regulatory news, clinical trial data, and nephrology research in this July 2025 recap.

In CKD patients with COVID-19, prior vaccination significantly reduced risks of major adverse kidney events and mortality, especially with ≥ 3 doses.

Host Brendon Neuen is joined by guests Tor Biering-Sørensen and Kristoffer Skaarup to discuss NUDGE-CKD and implementation trial design.

Moderate vitamin D deficiency was not associated with cognitive outcome risk, but severe deficiency was linked to both cognitive impairment and mortality.

Sarcopenia was most prevalent among those on hemodialysis, but prevalence varied based on assessment criteria and timing of lean muscle mass measurement.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

The first half of 2025 recap for nephrology spotlights renal FDA action, ERA 2025 Congress coverage, and updates in xenotransplantation.

Positive topline results showed patients who received 2 scheduled rilparencel injections experienced significant eGFR slope decline improvement.

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

The month in review spotlights renal regulatory news and clinical trial data as well as coverage of the 62nd European Renal Association Congress.

The CRL cited deficiencies previously identified at a third-party manufacturing vendor unrelated to OLC, and the Company plans to request a Type A meeting.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.

A RaDaR analysis from ERA 2025 provides insight into predictors of disease progression, outcomes in patients with Alport syndrome.

Study findings highlight the potential utility of cardiac catheterization as a targeted intervention in pre-kidney transplant cardiac risk stratification.

The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.

An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.